The decision by Scripius (previously Select Health Prescriptions) was made based on the cost of Dupixent, as well as because of an increased demand to use Dupixent for mild atopic dermatitis when the primary patient population is those with moderate to severe disease.
Scripius (previously Select Health Prescriptions) has removed Dupixent (dupilumab) from its formulary effective July 1, 2023, for new medication starts and Oct. 1, 2023, for current patients. Scripius is part of Select Health, a nonprofit health plan that serves more than 1 million members in Utah, Idaho, and Nevada.
Developed by Sanofi and Regeneron Pharmaceuticals, Dupixent is approved for multiple indications including atopic dermatitis and asthma. Last year, it was approved for several new uses, including for prurigo nodularis, a rare skin disorder. and for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis.
The decision to remove Dupixent from formulary was made based on the cost, Matt Mitchell, Pharm.D., AVP of Scripius told Formulary Watch. Duprixent has a list price of $3,587.92 per carton for two syringes or pens. It is administered by subcutaneous injection every two or weeks based on age and weight.
“The cost has grown exponentially over the last few years and it’s not slowing down,” he said. “There has been a lot of demand from patients and doctors to use Dupixent for mild atopic dermatitis (AD) when the primary patient population is severe AD. Dermatologists are not looking to really control the use.”
Mitchell said the rebates they were getting on Dupixent weren’t enough to justify continued coverage, and Scripius also wanted to have greater control over the usage of dermatology products.
Mitchell said alternatives being offered for atopic dermatitis include Rinvoq (upadacinib), Cibinqo (abrocitinib) and Adbry (tralokinumab-ldrm). Mitchell pointed out that Adbry has a similar mechanism of action to Dupixent and it has a much lower cost net. “It is a good option if patients are looking for something similar.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
Joseph Zabinski Advocates for Patient Trust in AI Adoption in Dermatology Care
April 18th 2024Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.
Read More